Amneal Pharmaceuticals, Inc. announced the completion of its acquisition of 100% of the membership interests in Kashiv BioSciences, LLC on August 10, 2026. The transaction combines upfront cash and stock payments with significant potential future milestone and royalty payments.
Key Details
- Upfront Consideration: The deal includes $375 million in cash (subject to adjustments) and the issuance of 28,942,108 shares of Amneal's Class A common stock to the sellers.
- Contingent Payments: Sellers are eligible for up to an additional $350 million in payments contingent upon achieving U.S. regulatory milestones for six specific Kashiv product candidates. They may also receive royalty payments over a 12-year period, equal to 25% of annual gross profits that exceed specified hurdles.
- Financing: To fund a portion of the acquisition, Amneal's subsidiary entered into an amendment to its term loan credit agreement to provide for a new incremental term loan of $350 million.
- Transaction Timeline: The acquisition was completed on August 10, 2026, based on a purchase agreement originally dated April 21, 2026.